Biogen's Salanersen Shows New Motor Milestones in SMA Children, Advancing to Phase 3 Trials
Summary
Biogen announced positive additional Phase 1b study results for salanersen, its investigational antisense oligonucleotide for spinal muscular atrophy (SMA). The data showed children with SMA, who had previously received gene therapy but had suboptimal clinical status, achieved new World Health Organization (WHO) motor milestones and experienced a 75% reduction in neurofilament light chain (NfL) levels, a marker of neurodegeneration. This encouraging progress, which builds on the company's stated pipeline focus, has led Biogen to initiate three global Phase 3 clinical trials (STELLAR-1, STELLAR-2, and SOLAR) to further evaluate salanersen across a broad SMA population. This advancement significantly de-risks the drug's development and highlights its potential as a valuable treatment option, either alone or as an add-on to existing gene therapies. Investors will closely watch the progress and outcomes of these pivotal Phase 3 studies, which are crucial for potential regulatory approval and future revenue generation.
At the time of this announcement, BIIB was trading at $184.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.7B. The 52-week trading range was $110.04 to $202.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.